Home / Health / Weight-Loss Injections Linked to Two Deaths in Northern Ireland
Weight-Loss Injections Linked to Two Deaths in Northern Ireland
9 Mar
Summary
- Two deaths in Northern Ireland potentially linked to weight-loss injections reported.
- Over 500 suspected adverse drug reaction reports submitted for GLP-1 medications.
- Cases include links to Mounjaro and unspecified semaglutide medications.
Two fatalities in Northern Ireland are being examined for a potential connection to weight-loss injections, with reports submitted to the MHRA. Over the past two years, more than 500 suspected adverse drug reactions related to GLP-1 medications have been reported in the region. These drugs, including brands like Wegovy and Mounjaro, are used for weight management and diabetes treatment.
The investigations involve two individuals, a man and a woman aged in their 40s and 60s. One case is linked to Mounjaro, while the other is associated with an unspecified semaglutide medication. The MHRA has stated that a suspected reaction report does not confirm the drug as the cause, noting that other health issues could be responsible.
Over the two-year period, six cases of acute pancreatitis were also reported, with some linked to Mounjaro and Ozempic. The MHRA issued a warning about pancreatitis risks in January. While an estimated 1.6 million adults in Great Britain have used GLP-1s for weight loss, access in Northern Ireland is more restricted, primarily for type 2 diabetes patients or via private prescription for those with a BMI over 30.
Data shows a significant increase in reports from Northern Ireland, with 458 in 2025 compared to 53 in 2024. Among the total reports, 242 were serious, including one involving a child aged nine or under. Both Mounjaro and Wegovy manufacturers emphasize patient safety and encourage reporting of side effects.
